188 related articles for article (PubMed ID: 38494849)
1. Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.
Moradi Hasan-Abad A; Arbabi M; Gilasi H; Motedayyen H
Int J Immunopathol Pharmacol; 2024; 38():3946320241239202. PubMed ID: 38494849
[No Abstract] [Full Text] [Related]
2. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
[TBL] [Abstract][Full Text] [Related]
3. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
[TBL] [Abstract][Full Text] [Related]
5. A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran.
Soltani S; Matin BK; Gouya MM; Zahraei SM; Moradi G; Chehri O; Soofi M; Moradinazar M; Shadmani FK; Kalantari M; Khajeha H; Emamian MH; Najafi F
BMC Public Health; 2023 Jul; 23(1):1415. PubMed ID: 37488541
[TBL] [Abstract][Full Text] [Related]
6. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran.
Pourakbari B; Mirbeyk M; Mahmoudi S; Hosseinpour Sadeghi RH; Rezaei N; Ghasemi R; Esfandiari F; Mamishi S
J Med Virol; 2022 Dec; 94(12):5669-5677. PubMed ID: 35883215
[TBL] [Abstract][Full Text] [Related]
8. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
9. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects following COVID-19 vaccination in Iran.
Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
[TBL] [Abstract][Full Text] [Related]
13. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Antibody Levels Produced by Pfizer, AstraZeneca, and Sinopharm Vaccination in COVID-19 Patients in Erbil City-Iraq.
Majed SO
Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):103-112. PubMed ID: 37300682
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
17. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
Mauas R; Urueña A; Cecchini D; Strada ML; Arietti S; Cassetti I; Nogueira NF; Salazar AS; Rodriguez VJ; Jones DL; Alcaide ML
AIDS; 2023 May; 37(6):941-946. PubMed ID: 36728228
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Eybpoosh S; Biglari A; Sorouri R; Ashrafian F; Sadat Larijani M; Verez-Bencomo V; Toledo-Romani ME; Valenzuela Silva C; Salehi-Vaziri M; Dahmardeh S; Doroud D; Banifazl M; Mostafavi E; Bavand A; Ramezani A
PLoS Pathog; 2023 Nov; 19(11):e1011744. PubMed ID: 37910480
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
